Company intelligence / Profile preview

Dexcom

San Diego, California, United Statesdexcom.com ↗

Ownership: Public · DXCM
Employees: ~8000
Development stage: Other

Overview

Dexcom’s CGM systems are FDA-approved and widely used globally for real-time diabetes management. The latest product, Dexcom G7, offers industry-leading accuracy with a MARD of ~8.2%, customizable alerts for hypo/hyperglycemia, and seamless integration with smartphones and insulin pumps. Clinical studies have demonstrated improved glycemic control in both type 1 and type 2 diabetes patients using CGMs compared to traditional fingerstick methods.

Therapeutic areas: Endocrinology
Modalities: DeviceBiosensor technology (Glucose biosensing)
Industry: Physiological Monitoring

Partnerships

Tandem Diabetes Care (insulin pump integration)Past partnerships with Insulet Corporation & Animas Corporation for device integration

Financials

Market cap: $31.5B
Total revenue: $4.7B
Enterprise value: $31.1B

Beyond the preview

Go deeper on Dexcom.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dexcom.